Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Groups, Multicenter Study to Investigate the Effects of Canagliflozin on Insulin Sensitivity, Hepatic Fat Content and Beta Cell Function in Subjects With Type 2 Diabetes Mellitus
연구 개요
상세 설명
This is a double-blind (neither physician nor participants knows the treatment that the participant receives), randomized (the study medication is assigned by chance), placebo-controlled (an inactive substance is compared with a medication to test whether the medication has a real effect in a clinical study), parallel-groups study which will be conducted at 2 clinical research centers (CRC) in the US. Approximately 56 participants, ages 25-70 years, with T2DM inadequately controlled on either metformin monotherapy or combination therapy with metformin and a DPP-4 inhibitor, will be enrolled. The study has 3 phases: pre-treatment, double-blind treatment, and post-treatment.
Pre-Treatment Phase will consist of a screening visit (Week -5), 14 days Single- Blind Placebo Run-in period, followed by 14 days of Single-Blind Placebo Baseline Period, during which participants will be randomized (1:1) to one of 2 treatment groups, either canagliflozin or placebo. Double-Blind Treatment Phase begins on Day 1, and ends at approximately Week 25, during which participants will be assessed at least biweekly at outpatient visits or by telephone contact. Canagliflozin treatment will be initiated at 100 mg/day, with up-titration to 300 mg/day, consistent with the approved INVOKANA® US Prescribing Information 2013. During post-treatment phase, a follow-up visit will occur within approximately 28 days after the last dose of study drug.
At baseline and after 24 weeks of treatment with canagliflozin, hepatic and peripheral insulin sensitivity will be assessed using tracer labeled euglycemic clamp technique; hepatic fat content will be determined using 1H nuclear magnetic resonance spectroscopy (MRS); beta cell function (insulin secretion rate and beta cell glucose sensitivity) will be assessed during mixed meal tolerance test (MMTT); substrate oxidation and energy production rates will be measured using indirect calorimetry during euglycemic clamp and MMTT.
During the study, participants will remain on their stable dose regimens of metformin or combination metformin DPP-4 inhibitor therapy, unless the investigator considers dose modification to be medically necessary. The total study duration for each participant participating in this study will be up to approximately 34 weeks.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
California
-
San Diego, La Jolla, California, 미국
-
-
Florida
-
Gainesville, Florida, 미국
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Must have a diagnosis of T2DM for at least 3 months and be on either metformin monotherapy at a stable dose of >=1,000 mg per day or on combination therapy of metformin >=1,000 mg per day and a DPP-4 inhibitor at stable daily doses for at least 12 weeks prior to screening with an HbA1c of >=7.0% and <= 9.5% at Screening
- Fasting plasma glucose >=120 mg/dL and <=240 mg/dL at the Week -4 visit
- Fasting fingerstick glucose >=120 mg/dL and <=240 mg/dL performed at clinical research center on Day -14
- Must be medically stable on the basis of clinical laboratory tests performed at screening
Exclusion Criteria:
- Has a history of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or β-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
- Has claustrophobia or anxiety, related to previous negative experiences with magnetic resonance imaging procedures which cannot be managed with an anxiolytic drug
- Has a history of brittle or labile glycemic control, with widely varying glucose measurements
- Has proliferative diabetic retinopathy (based on an eye examination within one year prior to Screening), currently receiving or requiring treatment
- Has a history of 1 or more severe hypoglycemic episodes within 6 months before screening
- Has history of hereditary glucose-galactose malabsorption or primary renal glucosuria.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Canagliflozin (JNJ-28431754)
Each patient will receive canagliflozin 100 mg once daily during the first 4 weeks of the 25 weeks double-blind period, then the dose may be increased to 300 mg once daily, till the end of the period.
|
1일 1회 경구(입으로) 100mg 캡슐 1개
1일 1회 경구(입으로) 300mg 캡슐 1개
|
|
위약 비교기: Placebo
One placebo capsule taken orally (by mouth) once daily for approximately 28 days during the Pre-Treatment Run-In and the Baseline Periods, then during double-blind study for 178 days (approximately 24-25 weeks).
|
One placebo capsule (inactive medication) once daily.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Change from baseline in hepatic insulin sensitivity
기간: Baseline, 25 weeks
|
Baseline, 25 weeks
|
|
Change from baseline in peripheral tissue insulin sensitivity
기간: Baseline, 25 weeks
|
Baseline, 25 weeks
|
|
Change from baseline in liver fat content, determined using magnetic resonance spectroscopy (MRS)
기간: Baseline, 25 weeks
|
Baseline, 25 weeks
|
|
Change from baseline in insulin secretion rate (ISR) during mixed-meal tolerance test (MMTT)
기간: Baseline, 25 weeks
|
Baseline, 25 weeks
|
|
Change from baseline in beta-cell glucose sensitivity, determined as a slope of ISR vs. plasma glucose concentration during MMTT
기간: Baseline, 25 weeks
|
Baseline, 25 weeks
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Changes from baseline in substrate oxidation and energy production rates during MMTT and euglycemic clamp
기간: Baseline, 25 weeks
|
Baseline, 25 weeks
|
|
Changes from baseline in insulin clearance during MMTT and euglycemic clamp
기간: Baseline, 25 weeks
|
Baseline, 25 weeks
|
|
Change from baseline in suppression of free fatty acids (FFAs) during euglycemic clamp
기간: Baseline, 25 weeks
|
Baseline, 25 weeks
|
|
Changes from baseline in basal and postprandial plasma glucagon, FFAs and β-hydroxybutyrate during MMTT
기간: Baseline, 25 weeks
|
Baseline, 25 weeks
|
|
Change from baseline in renal threshold for glucose (RTG), estimated using an MMTT-based method
기간: Baseline, 25 weeks
|
Baseline, 25 weeks
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CR103062
- 28431754DIA1054 (기타 식별자: Janssen Research & Development, LLC)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
제2형 당뇨병에 대한 임상 시험
-
Postgraduate Institute of Medical Education and...완전한
-
Hangzhou SynRx Therapeutics Biomedical Technology...모병유방암 | 난소 암 | 고급 고형 종양 | 전이성 고형 종양 | BRCA 1/2 및/또는 HRD중국
카나글리플로진, 100mg에 대한 임상 시험
-
Biomea Fusion Inc.모병
-
MiMedx Group, Inc.Rho, Inc.; NBCD A/S; United BioSource, LLC종료됨
-
OrthoTrophix, Inc완전한
-
Abivax S.A.완전한궤양성 대장염폴란드, 벨기에, 스페인, 프랑스, 독일, 슬로베니아, 캐나다, 벨라루스, 헝가리, 이탈리아, 오스트리아, 영국, 체코, 세르비아, 슬로바키아, 우크라이나, 미국